A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 396 participants.

Also called NCT06857955

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose other
Phase
Phase 2
Enrolled
  • 396 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06857955
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Japan, Singapore (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06857955. Randomized; triple masking; primary purpose other. Start 2025-03-26 (actual); primary completion 2026-09-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Condition
Hypertension
Intervention (Other)
Saline
Intervention (Drug)
QCZ484
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06857955
Content hash
de8f19443841a4aa1ce273372c4484fc114f1de11aac6d627c885953c5e22b87